Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Francesco Vendrame received his medical degree from the University of Rome La Sapienza. He completed his residency in endocrinology, diabetes, and metabolism at the University of Rome La Sapienza and a fellowship in endocrinology, diabetes, and metabolism at the Barbara Davis Center for Childhood Diabetes. He also completed a research fellowship at the University of Miami Miller School of Medicine. -
Education & Training
Education
Post Graduate Training
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 5 clinical trials.
-
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
- Principal Investigator: Francesco Vendrame
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The broad aim of the current research is the development of new therapies that can prevent and/or cure the disease. To this end we plan to collect peripheral blood samples from people with T1D. Sera and peripheral blood mononuclear cells (PBMC) can then be used to test specific hypothesis in-vitro or stored for later use.
- Principal Investigator: Francesco Vendrame
- Study Phase: TBD
- Enrollment Status: Open
-
Comparing HDV-Insulin Lispro Versus Insulin Lispro Alone in Adults with Type 1 Diabetes Receiving Insulin Degludec
- Principal Investigator: Francesco Vendrame
- Study Phase: TBD
- Enrollment Status: Closed
-
In this study, researchers want to learn if finerenone works better than placebo in reducing the participants' kidney disease from getting worse when given in addition to standard of care (SOC) treatment. SOC is a procedure or treatment that medical experts consider most appropriate for a condition or disease. To find out how well finerenone works, the level of a protein (albumin) in the urine will be measured.The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, they will visit the study site at least 6 times.The study team will:- collect blood and urine samples- check the participants' vital signs such as blood pressure and heart rate- do a physical examination including height and weight- check the participants' heart health by using an electrocardiogram (ECG)- do pregnancy tests in women of childbearing potential
- Principal Investigator: Francesco Vendrame
- Study Phase: TBD
- Enrollment Status: Closed
-
The proposed study is a Phase I/IIa randomized, controlled clinical trial to evaluate CELZ-201 therapy as an intervention for the treatment of recent onset T1D. The objective is to determine the safety and efficacy of CELZ-201 administration, based on the timing and dose of CELZ-201 treatment. Subjects who meet eligibility criteria will be randomized to treatment or control groups, in a 2:1 ratio. Subjects in the Group I (Treatment Group, n=12) will receive standard of care for type 1 diabetes and CELZ-201 within 1 month from enrollment (within 180 days of diagnosis), and subjects in the Group II (Control Arm, n=6) and will only receive standard of care for type 1 diabetes.
- Principal Investigator: Francesco Vendrame
- Study Phase: Phase I/II
- Enrollment Status: Open